NARRATIVE/ PUBLIC HEALTH RELEVANCE There is increased awareness that non-allergic asthma exists in children, and obesity-related asthma is the most commonly reported form of pediatric non-allergic asthma. Obese asthmatic children are poorly responsive to existing asthma medications but there is no targeted therapy for non-allergic asthma since its underlying immune pathways are not well understood. Having identified the CDC42 pathway as a novel pathway associated with pediatric non-allergic obese asthma, we will investigate the cell type in which it is upregulated and identify proteins in signaling pathways downstream of CDC42 as potential targets for therapeutic intervention for obesity-related asthma.
|Effective start/end date||2/1/19 → 1/31/23|
- National Heart, Lung, and Blood Institute: $450,783.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.